An International, Double-blind, Randomized, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
To determine whether dapagliflozin (Farxiga)is superior to placebo, when added to standard of care, in reducing the composite of cardiovascular death or hospitalization. Farxiga is a drug for the treatment of diabetes and has been found to improve the quality of life for heart failure patients by promoting the reduction of glucose.
Available at the following location(s)
Do you need help with some of the labels on this page?
Read our glossary of terms